Key result
Simvastatin increased fasting plasma glucose compared to diabetic model rats at 4 and 12 weeks, indicating an adverse effect on glucose homeostasis.
Why the study?
Does simvastatin affect glucose homeostasis in streptozotocin-induced type 2 diabetic rats?
RCT (n=40)
Randomly divided into four groups
Does simvastatin affect glucose homeostasis in streptozotocin-induced type 2 diabetic rats?
In a rat model of type 2 diabetes, simvastatin administration worsened fasting plasma glucose levels, suggesting an adverse effect on glucose homeostasis.
Requires confirmation in other models and humans; does not support changes to statin use in diabetes.
Objective. To investigate the effect of simvastatin on glucose homeostasis in streptozotocin induced type 2 diabetic rats. Methods. Forty male Wistar rats were randomly divided into four groups. Normal control rats were fed with standard diet, others were fed with high-fat diet. Diabetic rats were induced by a single intraperitoneal injection of STZ. The simvastatin intervention rats were fed with simvastatin during the experiment process, and the simvastatin treatment rats were fed with simvastatin after diabetes rats were induced. We measured body weight, fasting plasma glucose, cholesterol, high-density lipoprotein cholesterol, and triglyceride after an overnight fast. Results. The FPG was higher in diabetic rats when compared to normal control ones; the simvastatin intervention rats had a higher FPG compared to the diabetic rats and were more easily be induced to diabetes at the end of 4 weeks, FPG level of simvastatin treatment rats was increased compared with diabetic model rats after 12 weeks. Conclusion. These data indicate that simvastatin intervention rats may cause hyperglycemia by impairing the function of islet β cells and have an adverse effect on glucose homeostasis, especially on FPG level.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2013) conducted an RCT in Type 2 diabetes (n=40). Simvastatin vs. Diabetic model rats and normal controls was evaluated on Fasting plasma glucose. Simvastatin increased fasting plasma glucose compared to diabetic model rats at 4 and 12 weeks, indicating an adverse effect on glucose homeostasis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: